We design the value story before we generate the evidence behind it
Most HEOR engagements start with a deliverable. Ours start with a question: what does each payer need to believe, and what evidence will make them believe it? Our consultants map evidence gaps against HTA expectations market by market, then build the SLRs, models and dossiers that close them — designed once, deployed deliberately across markets.
Strategic advisory
Before any deliverable is scoped, our consultants work with your leadership to answer the questions that determine whether the evidence will change a decision.
- Integrated evidence-generation plans aligned to launch and HTA timelines
- Global market readiness: country-by-country assessment of where your evidence will travel and where it will stall — with a prioritised evidence and localisation roadmap
- Launch and submission sequencing: which markets, in what order, and why
- Early value assessment and target product profile stress-testing
- Payer evidence-expectation audits across US, EU, UK, Japan and APAC
Evidence generation capabilities
Systematic Literature Reviews
Protocol-driven SLRs and targeted reviews compliant with PRISMA, Cochrane and HTA-body requirements.
Meta-analysis & NMA
Pairwise and network meta-analyses, indirect treatment comparisons and feasibility assessments.
Economic Modelling
Cost-effectiveness, budget-impact and cost-of-illness models built to NICE, CADTH and ICER standards.
HTA & Value Dossiers
Global value dossiers, AMCP dossiers and country-specific HTA submissions and adaptations.
Global Evidence Localisation & Affiliate Support
Core evidence designed once and adapted per market, with governed, evidence-grounded responses to affiliate and payer questions.
Burden of Illness & PRO Evidence
Epidemiological, humanistic and economic burden assessments, plus PRO instrument selection and psychometric evidence.
AI-assisted strategic analysis
Not every project needs it. For the engagements below, our consultants draw on in-house AI tools to analyse faster and more consistently — and you receive the insight as a strategic report with recommendations.
Global market-readiness assessment
For multi-market launches, we use in-house AI tools to analyse your evidence assets against each target market's HTA and payer requirements — every finding validated by senior consultants — and deliver a readiness verdict, gap roadmap and submission sequence your leadership can govern by.
HTA readiness assessment
Where a national HTA submission is on the horizon, we benchmark your evidence package against the questions assessors will ask — using in-house AI tools to structure the gap analysis.
Questions clients ask about HEOR & Global Market Access Strategy
HEOR rarely stands alone. Most engagements draw on our Competitive Intelligence, Real World Evidence Strategy and Scientific Communications capabilities.
What does an HEOR consultancy actually deliver?+
Systematic literature reviews, network meta-analyses, cost-effectiveness and budget-impact models, global value dossiers and HTA submissions — preceded by an evidence strategy that defines what each payer needs to believe and which evidence will make them believe it.
Which HTA bodies do you build models and dossiers for?+
NICE, SMC, G-BA/IQWiG, HAS, AIFA, CADTH, PBAC, ICER and the EU Joint Clinical Assessment, plus US commercial payers via AMCP Format dossiers. Core evidence is designed once and adapted market by market.
When should HEOR work start?+
Ideally during Phase II, when endpoints, comparators and PRO instruments can still be shaped to meet HTA expectations. Late-stage engagement is common, but early value assessment prevents evidence gaps that are expensive to close after pivotal trials.
Do you use AI in systematic reviews and models?+
Yes — in-house AI tools accelerate screening, extraction and gap analysis, with every decision validated by senior consultants and a second human reviewer. Clients receive audit-ready, HTA-grade deliverables.
Scope a HEOR & Global Market Access Strategy engagement
Share your objectives, timelines and target markets. We respond within one business day with next steps.